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Abstract
Merkel cell carcinoma (MCC) is a relatively uncommon but highly lethal form of skin cancer. A majority of MCC tumors carry
DNA sequences derived from a newly identified virus called Merkel cell polyomavirus (MCV or MCPyV), a candidate etiologic
agent underlying the development of MCC. To further investigate the role of MCV infection in the development of MCC, we
developed a reporter vector-based neutralization assay to quantitate MCV-specific serum antibody responses in human
subjects. Our results showed that 21 MCC patients whose tumors harbored MCV DNA all displayed vigorous MCV-specific
antibody responses. Although 88% (42/48) of adult subjects without MCC were MCV seropositive, the geometric mean titer
of the control group was 59-fold lower than the MCC patient group (p,0.0001). Only 4% (2/48) of control subjects
displayed neutralizing titers greater than the mean titer of the MCV-positive MCC patient population. MCC tumors were
found not to express detectable amounts of MCV VP1 capsid protein, suggesting that the strong humoral responses
observed in MCC patients were primed by an unusually immunogenic MCV infection, and not by viral antigen expressed by
the MCC tumor itself. The occurrence of highly immunogenic MCV infection in MCC patients is unlikely to reflect a failure to
control polyomavirus infections in general, as seroreactivity to BK polyomavirus was similar among MCC patients and
control subjects. The results support the concept that MCV infection is a causative factor in the development of most cases
of MCC. Although MCC tumorigenesis can evidently proceed in the face of effective MCV-specific antibody responses, a
small pilot animal immunization study revealed that a candidate vaccine based on MCV virus-like particles (VLPs) elicits
antibody responses that robustly neutralize MCV reporter vectors in vitro. This suggests that a VLP-based vaccine could be
effective for preventing the initial establishment of MCV infection.
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Introduction
The Polyomaviridae are a diverse family of non-enveloped DNA
viruses named for some family members’ ability to cause various
types of tumors in experimentally challenged animals. Although
BK and JC polyomaviruses (BKV and JCV) are highly prevalent
in human populations, neither virus has been clearly shown to
cause cancer in humans (reviewed in [1]). A previously
unidentified polyomavirus was recently found associated with
Merkel cell carcinoma (MCC), a relatively unusual form of skin
cancer that tends to strike elderly or immunocompromised
individuals ([2], reviewed in [3,4]). Sequences from this new virus,
called Merkel cell polyomavirus (MCV or MCPyV), have been
confirmed to be present in a majority of MCC tumors [5–8]. The
viral DNA is maintained as a circular episome during productive
infection but is clonally integrated into the cellular DNA of MCV-
positive MCC tumors. Integrated viral genomes carry a charac-
teristic pattern of mutations of the large T antigen gene that
produce truncating deletions of the T antigen protein [9]. The
mutations abrogate the protein’s ability to drive replication of the
viral DNA but preserve regions with predicted oncogenic
potential. In some integrated viral genomes, deletions also occur
in the late region of the virus encoding the viral capsid proteins
[5,10]. Taken together, the available evidence suggests that
nonproductive integration of MCV genomic DNA into the host
cell’s DNA is an etiologic factor underlying the development of
most cases of MCC.
Recent serological studies using recombinant MCV capsid
proteins have shown that about 50–80% of adults display
detectable MCV-specific antibody responses [11,12]. This suggests
that MCV infection is common, but only rarely leads to MCC.
Although a majority of adults are seropositive for MCV, our initial
serological studies suggest that some individuals display stronger
humoral responses to MCV than others. To more accurately
quantitate MCV-specific serum antibody responses in human
subjects, we developed an assay for measuring antibody-mediated
PLoS Pathogens | www.plospathogens.org 1 September 2009 | Volume 5 | Issue 9 | e1000578
neutralization of cellular transduction with an MCV-based
reporter vector. The assay employs very low viral particle doses,
allowing improved accuracy and reproducibility compared to
previously-reported MCV serological methods.
Unlike enzyme-linked immunosorbent assays (EIAs), which
simultaneously measure both neutralizing and non-neutralizing
antibodies, viral neutralization assays have the useful feature of
measuring only the subset of antibodies that are likely to confer
protection against infection. Neutralization assays have therefore
been used for characterizing candidate vaccines [13]. Although
VLP-based vaccines against viruses such as human papillomavirus
(HPV) and hepatitis B virus are highly immunogenic, it appears
that VLPs based on some polyomavirus types can be poorly
immunogenic in animal model systems [14]. Using the MCV
reporter vector-based neutralization assay, we show that MCV
VLPs elicit robust functional antibody responses and thus could
potentially be employed in vaccines aimed at preventing MCV
infection.
Results
Development of MCV-based reporter vectors
Isolation of infectious MCV virions has not yet been reported.
To simulate MCV infection in vitro, we generated gene delivery
vectors employing the VP1 and VP2 capsid proteins of MCV. The
MCV reporter vectors were produced by transfecting human
embryonic kidney-derived 293TT cells [15] with expression
plasmids carrying codon-modified versions of MCV VP1 and
VP2 genes of MCV isolate 339 [2,12]. For initial optimization
experiments, the VP1 and VP2 expression plasmids were co-
transfected with a reporter plasmid encoding GFP. The transfect-
ed cells produced high yields of capsids with a VP1:VP2 ratio of
about 6:1 [12]. A fraction of the particles encapsidated the GFP
reporter plasmid. The GFP transducing potential of the MCV-
based reporter vector particles was titered on HeLa cells, which
were found to be permissive for transduction with the GFP
reporter gene.
Previously-identified polyomaviruses encode a minor capsid
protein, VP3, whose translation initiates from an in-frame
methionine (Met) codon within the VP2 open reading frame.
However, MCV lacks the conserved Met-Ala-Leu motif that forms
the amino-terminus of all previously described polyomavirus VP3
proteins. We generated expression plasmids encoding possible
alternative VP3 proteins initiated from MCV VP2 Met46 or
Met129 codons. While inclusion of VP2 improved the infectivity of
the MCV reporter vector by about five-fold, compared with using
VP1 alone, inclusion of the candidate VP3 expression constructs
either slightly reduced or did not affect reporter vector infectivity
(data not shown). The results suggest that, in contrast to other
polyomaviruses, MCV may not encode a functional VP3 protein.
It has recently been shown that bacterially-expressed VP1
capsomers based on MCV isolate 350 are serologically distinct
from MCV339 capsomers [11]. Like MCV339, MCV350 was
isolated from an MCC tumor. We attempted to generate reporter
vectors based on the MCV350 VP1 protein. However, the VP1
protein of MCV350 was rapidly degraded to undetectable levels in
293TT cell lysates (Figure S1). Attempts to purify MCV350
capsids by ultracentrifugation were similarly unsuccessful (data not
shown). The results indicate that MCV350 encodes a structurally
defective VP1 protein, possibly due to mutations arising during
tumorigenesis. This concept is consistent with the fact that
MCV350 VP1 residues His288, Ile316 and Asn366 differ from the
consensus Asp, Arg or Asp residues (respectively) that are highly or
absolutely conserved among all known polyomaviruses, including
MCV339 and a variety of more recently described MCV VP1
isolates [16].
Development of an MCV neutralization assay
The transducing potential of a viral vector can typically be
blocked by antibodies capable of neutralizing the virus on which
the vector is based. To develop a reporter vector-based MCV
neutralization assay, we employed a highly sensitive Gaussia
luciferase (Gluc) reporter gene. 293TT cells [15], which stably
express SV40 large T antigen, were used as an infection target.
Successful transduction of 293TT cells results in T antigen-
mediated amplification of the transduced Gluc reporter plasmid,
which carries the SV40 origin of replication. The MCV-Gluc/
293TT assay is highly sensitive, with MCV-Gluc reporter vector
doses of 80 pg of VP1 per well (roughly 8 pM with respect to VP1
or roughly 100 virions per cell) yielding signal to noise ratios of
1000:1.
A pooled human serum sample was serially diluted and tested
for the ability to neutralize MCV vector-mediated transduction of
the Gluc gene into cells. 50% neutralizing titer (EC50) was
calculated by fitting a sigmoidal dose-response curve to lumino-
metric values for the dilution series. The calculated EC50 for the
pooled serum occurred at a 17,90062500-fold serum dilution
(Figure 1). Serum from a rabbit inoculated with MCV VLPs (see
below) also robustly neutralized the infectivity of the MCV-Gluc
reporter vector, while preimmune serum from the rabbit was less
than 50% neutralizing at the 1:100 serum dilution. Since the pre-
immune rabbit serum showed non-specific neutralizing effects at
dilutions less than 1:100, this dilution was chosen as a cutoff for
subsequent work.
A control experiment using IgG purified out of the pooled
human serum gave a neutralization curve that overlapped that of
the original serum (EC50 = 14,90062200). Conversely, stripping
the pooled serum of immunoglobulins reduced the EC50 by nearly
40-fold (data not shown). The results demonstrate that the MCV
vector-neutralizing activity of serum diluted 1:100 or greater is
entirely or almost entirely attributable to antibodies.
Author Summary
For more than 50 years it has been known that some
polyomavirus types can induce cancer in experimental
animals. However, associations between the various
polyomaviruses known to chronically infect most humans
and the development of cancer have been difficult to
uncover. Last year, DNA from a new human polyomavirus,
called Merkel cell polyomavirus (MCV), was found embed-
ded in an uncommon form of skin cancer called Merkel cell
carcinoma. Emerging evidence indicates that most adults
display detectable immune responses to MCV, suggesting
that most individuals eventually become infected with the
virus. In this study, we investigate antibodies that directly
bind the protein coat of MCV, thereby obstructing its
ability to penetrate cultured cells. We found that the
magnitude of antibody responses against MCV varies
dramatically among normal adults. Interestingly, patients
suffering from MCV-associated Merkel cell carcinoma
display uniformly strong antibody responses against the
virus. This suggests that the development of Merkel cell
carcinoma is preceded by an unusually robust MCV
infection. It is currently unclear whether MCV infection
may also be associated with additional diseases aside from
Merkel cell carcinoma. Quantitation of immune respon-
siveness to the virus, using techniques reported here,
could help identify such links.
Antibody Responses to MCV
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Serological cross-reactivity between BKV and SV40, which
occupy a phylogenetic cluster that also includes JCV, has
previously been documented (reviewed in [1] ). MCV is part of
a different phylogenetic cluster that includes African green
monkey B-lymphotropic polyomavirus (LPV) and murine poly-
omavirus (MPyV). It has long been suspected that an LPV-like
virus infects humans [17]. Kean and colleagues have recently
confirmed that 10–20% of human subjects display LPV-specific
antibody responses in a capsomer-based EIA. The report further
demonstrated that antibodies specific for MCV do not cross-react
with LPV [11]. To verify that the vector-based MCV neutraliza-
tion assay is specific for MCV, we developed a neutralization assay
based on MPyV, which, in contrast to LPV, is not thought to
infect humans. Neither the pooled human serum nor the MCV-
specific rabbit serum inhibited transduction of 293TT cells by the
MPyV reporter vector (Figure 1). In contrast, the MPyV reporter
vector was neutralized by control serum from a rabbit immunized
with MPyV VP1 [18]. Similar results were observed when the
MPyV reporter vector and sera were applied to murine NIH-3T3
cells (data not shown). We also developed an LPV reporter vector
and confirmed the observations of Kean and colleagues that 10%
of serum samples from paid donors had very low neutralizing titers
to LPV reporter vectors (data not shown). The majority of donors
with neutralizing LPV titers did not have significant MCV
neutralizing titers, although other sera did (see below). The results
demonstrate that neutralizing antibodies in human sera are
specific for MCV and not one of MCV’s known near relatives.
Quantitation of MCV-neutralizing antibodies in individual
human sera
Under ideal circumstances, the EC50 values observed in
neutralization assays and VLP-based EIAs reflect the affinity of
relevant antibodies for the viral capsid. This requires that the assay
conditions satisfy the assumptions of the law of mass action. This
concept was first put forward in 1933 by Andrewes and Elford as
the ‘‘percentage law,’’ which states that the virus-neutralizing titer
of an antibody preparation is not affected by the amount of virus,
so long as the antibody is in excess over the virus [19–21]. In other
Figure 1. Quantitation of MCV-specific neutralizing antibodies in human serum. Top panel: Pooled human serum and IgG purified out of
the pooled serum were serially diluted and tested in an MCV reporter vector-based neutralization assay. Rabbit sera collected before or after
immunization with MCV VLPs were also tested. A sigmoidal dose-response curve was fitted to the data points. Dashed lines show 95% confidence
intervals. Bottom panel: serum samples indicated were diluted 1:500 and tested for inhibition of MPyV-mediated Gluc transduction (measured in
relative light units, RLUs). Error bars in both panels show standard error of the mean.
doi:10.1371/journal.ppat.1000578.g001
Antibody Responses to MCV
PLoS Pathogens | www.plospathogens.org 3 September 2009 | Volume 5 | Issue 9 | e1000578
words, if the concentration of antigen in the assay approaches or is
in excess of the affinity constants of the antibody/antigen
interactions being measured, antibody is stripped from solution
before affinity-driven equilibrium between bound and unbound
antibody can be reached. As a consequence, the EC50 begins to
reflect the dose of antigen, rather than the affinity of the
interaction. A straightforward strategy for testing whether a
seroassay complies with the percentage law is to examine EC50
values for various antigen doses [22–24]. Under compliant
conditions, the EC50 is insensitive to antigen dose.
Neutralization assays of the pooled human serum using MCV-
Gluc doses ranging from 16 to 240 pg of VP1 per well gave
neutralization curves that were not significantly different, with
EC50 values ranging from 15,600 to 17,900 (Figure 2). In contrast,
the use of MCV-Gluc doses of 800 pg or 1.2 ng of VP1 per well
resulted in lower EC50 values (7600 and 2800, respectively). VLP-
based EIAs using VP1 doses of 100 or 33 ng per well gave
dramatically lower EC50 values (230 and 460, respectively,
Figure 2). The results indicate that, using standard antigen doses,
the neutralization assay complies with the percentage law and the
EIA does not. Optimized polyomavirus VLP EIA methods use
VP1 doses ranging from 6 to 200 ng per well [25–27], suggesting
that polyomavirus VLP EIA could not be adapted to the
,240 pg/well doses required to comply with the percentage
law. The data indicate that the neutralization assay offers a more
accurate and sensitive measurement of serological responsiveness
to MCV than the EIA. The fact that the neutralization assay is
insensitive to virion dose would also be expected to make it more
reproducible than the EIA.
To further explore the relative accuracy of the neutralization
assay, we tested serial dilutions of sera from a selected set of 10
blood donors whose EIA reactivity was robust enough to allow
calculation of an EC50 value [12]. The blood donors were
compared to 12 MCC patients whose tumors were found to
harbor MCV DNA sequences. As seen in Figure 3, the
neutralization assay allowed improved discrimination between
the two groups’ seroresponsiveness to MCV. While the EIA
suggested a 4-fold difference between the geometric mean titers
(GMT) of the blood donor and MCC patient groups (GMT of 876
and 3,390, respectively), the neutralization assay revealed a .10-
fold difference (GMT of 21,500 and 222,000, respectively)
between the two groups, with correspondingly stronger p values
(Figure 3). Furthermore, EIA EC50 values for individual subjects
were an average of 50-fold lower than their neutralizing EC50
values (Figure S2), confirming the greater accuracy of the
neutralization assay.
MCC patients display unusually strong MCV-neutralizing
responses
It was striking that subjects with MCC displayed significantly
higher neutralizing titers than a selected group of strongly
seropositive blood donors (Figure 3). To better characterize this
apparent difference; we tested a set of 48 sera from older adults
(age range 47–75 years) without diagnosed MCC. The control
subject sera were compared to a total of 21 MCV-positive MCC
patients (age range 14–95 years). As seen in Figure 3, MCV+ MCC
patients invariably displayed high titer MCV-neutralizing respons-
es, with a GMT of 160,000. Control subjects, in contrast, showed
Figure 2. MCV neutralization assay complies with the percentage law. Pooled human serum was tested in MCV neutralization assays (top
panel) or EIAs (bottom panel) employing various doses of VP1 antigen (VP1 mass per assay well indicated in legend). Percent neutralization was
calculated by standardization to calculated maximum RLU values. EIA curves were standardized to calculated maximum OD values. In both panels,
standard VP1 doses are plotted as dark blue triangles.
doi:10.1371/journal.ppat.1000578.g002
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a broad, continuous distribution of neutralizing titers, with a
significantly lower GMT of 2700 (p,0.0001). Only 7/48 (15%) of
control subjects displayed titers within or above the interquartile
range of the MCV+ MCC patient population.
The prevalence of MCV-neutralizing activity in the control
subject population was high, with 88% (42/48) of the subjects
displaying EC50 values falling within the tested range of serum
dilutions. It is not clear whether sera with titers below 100 are
weakly MCV seropositive or rather contain non-specific neutral-
izing activity, as was observed for the pre-immune rabbit serum
(Figure 1). The neutralization assay results confirm recent findings
showing that MCV-specific seroprevalence is common among
older adults and suggests that the 67% EIA-based seroprevalence
observed in this same group of subjects [12] may have been a
slight underestimate.
The presence of high MCV-specific titers in all the MCV-positive
MCC patients could, in theory, reflect an immunocompromised state
in which latent polyomavirus infections are allowed to resurface,
triggering strong virus-specific antibody responses. To test this
hypothesis we evaluated sera from the same set of control subjects
and MCC patients for the presence of anti-BKV antibodies using a
BKV-based reporter vector [28]. There was no apparent correlation
between BKV and MCV titers in individual subjects (data not
shown), suggesting a lack of general reactivation of polyomaviruses as
well as a lack of cross-reactivity between the two virus types in the
neutralization assays. The BKV GMT was 5,100 for control subjects
and 2,300 for MCV-positive MCC patients (Figure 3). This slight
difference in titer was not statistically significant.
Sera from a set of six MCC patients whose tumors did not
contain detectable amounts of MCV DNA were also tested in the
neutralization assay. 4/6 of the MCV2 MCC patients displayed
very low titers in the neutralization assay (Figure S3).
The incidence of MCV seroresponsiveness has been shown to
increase with subject age, reaching an apparent maximum
prevalence in late adulthood [11,12]. Age-specific trends in the
MCV-neutralizing titers of the control subjects shown in Figure 4
were not evident, perhaps in part because the distribution of ages
is clustered about the mean (5665.7 years, Figure S3).
Interestingly, adult MCV+ MCC patients displayed a marginally
significant inverse correlation between subject age and MCV-
neutralizing titer (p = 0.0497, Spearman r=20.4443, Figure S3).
The trend is reminiscent of the gradual age-related decline in
BKV-specific antibody responses observed in cross-sectional
studies of adults [29]. The data indicate that the higher MCV-
specific titers of the MCC patients are unlikely to be attributable
simply to their more advanced average age relative to the control
subjects.
Investigation of capsid protein expression in MCC tumors
One possible explanation for the higher MCV-specific antibody
titers of MCV+ MCC subjects could be that the MCC tumor itself
serves as a source of MCV capsid protein immunogen. One
previous report has documented an MCC tumor that carries a VP1
gene with a large internal deletion that would presumably render
the protein incapable of forming intact capsids [5]. The current
study suggests that the MCC350 tumor would likewise be
genetically incapable of expressing conformationally intact capsids
or of making stable protein. However, it remains conceivable that
other MCC tumors might produce MCV capsid protein. To
address this question, we performed immunohistochemical staining
of MCC tumor sections. Since sections of the tumors from subjects
on whom the serological studies were performed were unavailable,
we selected 10 MCC tumors that had previously scored positive for
expression of MCVT antigen [10]. Unfortunately, matched sera for
this set of tumors were unavailable.
MCC tumor sections were co-stained with MCV VLP-specific
rabbit serum and antibody CM2B4, which is specific for MCV T
antigen [10]. To generate positive controls, HeLa cells were
transfected with expression constructs encoding either MCV VP1
or MCV T antigen. The transfected cells were paraffin-embedded
and sectioned in a manner analogous to the preparation of the
MCC tumor sections. As seen in Figure 5, T antigen and VP1
were readily detectable in the appropriate HeLa control cells.
MCC tumor cells stained positive for MCV T antigen but negative
for MCV VP1. Some MCC tumor sections were co-stained with
antibody to cytokeratin-20 (CK20, a histological marker of MCC
tumor cells) instead of CM2B4. While CK20 was readily visualized
in MCC tumor cells, VP1 was again not detected in the tumor
cells (Figure 5). 10/10 MCV T antigen-positive MCC tumors
analyzed displayed an absence of VP1 staining. The results
indicate that most MCC tumors produce little or no MCV VP1.
Development of a candidate MCV vaccine
To investigate the functional immunogenicity of MCV VLPs,
serum from a rabbit inoculated with purified MCV VP1/VP2
VLPs was tested using the reporter vector neutralization assay.
Hyperimmune serum from the animal displayed a neutralizing
titer of 1.9 million60.4 million (Figure 1, top panel).
Five mice were also administered MCV VLPs. Two of the mice
received an initial prime of VLPs without adjuvant, while three
other mice received the VLP prime in complete Freund’s
adjuvant. All the mice received a booster dose of VLPs in
incomplete Freund’s adjuvant. Mice receiving the unadjuvanted
prime displayed neutralizing EC50 titers of 0.9 and 3.2 million,
while the three mice receiving the priming dose with adjuvant
displayed titers of 1.1, 1.1 and 1.6 million. The results show that
Figure 3. Comparison of EIA to neutralization assay for
individual samples. Serum samples from a selected set of 10
robustly seropositive blood donors (+BD) and 12 MCV+ MCC patients
(MCC) were serially diluted and tested in MCV VLP-based EIA or MCV
neutralization assay. EC50 values (y-axis) were calculated for each serum
sample. Bars within the plots show the geometric mean, with 95%
confidence interval.
doi:10.1371/journal.ppat.1000578.g003
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MCV VP1/VP2 VLPs can elicit potent MCV vector-neutralizing
antibody responses in a vaccine setting.
Discussion
The results show that, while a majority of older adults are
exposed to MCV, the magnitude of serological responsiveness to
the viral capsid proteins varies continuously across a 10,000-fold
range. Compared to control subjects, all MCV+ MCC patients in
the study displayed unusually high-titer humoral responses to
MCV. In an initial EIA-based study establishing the prevalence of
serological responsiveness to MCV in human subjects, we found
that sera from MCV+ MCC patients contained MCV-specific
antibodies at levels that appeared to saturate the EIA at the tested
1:500 serum dilution [12]. EIA-saturating responses were less
common among various groups of control subjects. In the current
report we extend these observations, providing accurate scalar
measurements of human seroresponsiveness to MCV.
The human polyomaviruses BKV and JCV are thought to
establish latent infections that persist for decades [30]. For these
virus types, reactivation from latency and active shedding of
virions, which can occur under conditions of immunosuppresion,
is positively correlated with serum antibody responses to the viral
capsid proteins [27,31,32]. Thus, strong seroresponsiveness against
MCV may record a history at some point of relatively
uncontrolled MCV infection. Although it seems paradoxical that
MCV infection would not be controlled by antibody responses
expected to neutralize the infectivity of the virus, it is possible to
imagine that MCV, like BKV and JCV, is able to establish a
reservoir of latently infected cells. Such latent infections might be
resistant to clearance by neutralizing antibodies and thus could
serve as a durable source of immunogenic virions, even in the face
of effective neutralizing antibody responses. Alternatively, a
putative delayed immune response might have resulted in a high
viral load that ultimately did induce high antibody levels. Since
responses to BKV were similar in MCC patients and control
subjects, it appears that MCC is associated with a specific failure to
control MCV infection, as opposed to a more generalized failure
to control all polyomavirus infections.
It is important to note that about a third of control subjects we
studied displayed MCV responsiveness in the same range as MCV+
MCC patients (Figure 4). In light of the rarity of MCC (roughly 1500
cases per year in the United States, [33] reviewed in [34]), the results
imply that most individuals who mount strong serological responses
against MCV will not ultimately develop MCC. This is reminiscent
of data indicating that exposure to ultraviolet light correlates with
(but obviously does not guarantee) the development of MCC
(reviewed in [4,6]). Taken together, the results suggest a model in
which uncontrolled MCV infection is one of multiple carcinogenic
insults underlying the development of most cases of MCC.
Although MCV DNA has been detected in skin, bowel, lymph
node, and respiratory tract samples [2,35–37] the normal site or
sites of productive MCV replication and the character of actively
replicating MCV strains remains unclear. It is also unclear
whether MCV infection may be a factor in other forms of disease
in addition to MCC. MCV DNA sequences have recently been
detected in a fraction of non-melanoma, non-MCC skin cancers,
but a causal link between MCV and these forms of cancer has not
yet been clearly established [38,39]. While it is formally possible
that neutralization of authentic MCV in the bona fide cellular
target might differ with neutralization in 293TT cells, our results
suggest that the current assay provides quantitative analysis of
seroreactivity to a large subset of MCV neutralizing antibodies as
reflected by the high rates of seropositivity detected in both MCC
Figure 4. MCV-positive MCC patients invariably display strong
MCV-neutralizing antibody responses. Sera from a set of subjects
without MCC (control) and MCV+ MCC patients were serially diluted and
tested using the neutralization assay. EC50 values for each serum are
shown (y-axis). Black bars show the geometric mean EC50 (with 95%
confidence interval) for each group. Samples with projected EC50 values
falling below the bottom of the assay’s standard dilution series (dotted
line) were plotted at 100. Top panel: Anti-MCV titers for 48 controls and
21 MCV+ MCC patients. The difference between the two groups was
statistically significant (p,0.0001, Mann-Whitney non-parametric 2-
tailed t test). Bottom panel: Anti-BKV titers for 48 controls and 16 MCV+
MCC patients. The difference between these two groups was not
statistically significant.
doi:10.1371/journal.ppat.1000578.g004
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patients and in the general population. This assay can reveal
potential links between the immunogenic infection with the virus
and a disease state, such as MCC. Compared to VLP-based EIAs,
the neutralization assay presented in this work demands less
operator hands-on time and provides substantially more accurate
results. Thus, the neutralization assay should become a preferred
technique for investigating possible correlations between highly
immunogenic MCV exposure and other disease states, including
non-MCC cancers. It may be possible to increase the throughput
of the assay by initially identifying high-titer subjects using a single
serum dilution point. For example, a cutoff of 90% neutralization
at the 1,600-fold serum dilution would have correctly identified all
subjects with EC50 titer values greater than 20,000.
The apparent absence or very low level of VP1 protein
expression we have observed in MCC tumors confirms previous
suggestions that the virus does not actively replicate in MCC
Figure 5. MCC tumors do not express detectable amounts of MCV VP1 protein. Immunohistochemical staining was performed on sections
of paraffin-embedded MCC tumors (panels C–F) or paraffin-embedded HeLa control cells transfected with expression constructs encoding MCV T
antigen (panel A) or MCV VP1+VP2 (panel B). Cells in panel A were stained with CM2B4, a monoclonal antibody specific for MCV T antigen (green
secondary). Cells in panel B were stained with an MCV VLP-specific rabbit serum (red secondary). The MCC tumor section in panels C and D was co-
stained with CM2B4 and the rabbit anti-VLP serum. Panel C shows MCV T antigen signal (green secondary), panel D shows MCV VLP signal (red
secondary). Panels E and F show staining of a section from a different MCC tumor. Panel E shows CK20 staining (green secondary). Panel F shows
staining MCV VLP staining (red secondary).
doi:10.1371/journal.ppat.1000578.g005
Antibody Responses to MCV
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tumors. The finding is also consistent with the concept that the
tumors are under immunological pressure favoring reduced
expression of capsid proteins. This reduced expression could be
due either to mutations in VP1, as appears to be the case for
MCV350, or due to control of VP1 expression at transcriptional,
RNA processing or translational levels. In any event, it appears to
be unlikely that robust MCV capsid-specific antibody responses
are directly primed by the MCC tumor, suggesting that strong
seroresponsiveness to MCV indicates a prior history of active
MCV infection of non-tumor or (pre-tumorous) tissues.
In human papillomavirus (HPV) infections, the virally induced
cellular changes that lead to development of cancer occur in the
absence of a productive viral infection and in the presence of
existing neutralizing antibodies. A prophylactic HPV VLP-based
vaccine that generates neutralizing antibodies seems to be sufficient
to block the development of cancer by preventing the initial
establishment of infection [40]. Development of MCC likewise
seems to occur in the presence of effective humoral responses, but a
prophylactic vaccine might nevertheless be effective for preventing
the initial establishment or dissemination of MCV infection. In
addition, more research might unveil MCV as a causative agent in
more common public health threats, if so, a prophylactic vaccine
might be beneficial. To begin to explore the idea that a VLP-based
vaccine against MCV might be effective, we immunized animals
with a candidate MCV vaccine composed of MCV VP1/VP2
VLPs. All the vaccinated animals displayed strong MCV vector-
neutralizing antibody responses, with 50% neutralizing titers of
roughly one million-fold serum dilution. This is comparable to the
titers of animals administered HPV VLP-based vaccines [41], and
higher than titers observed in animals receiving JCV VLPs,
particularly when the JCV VLPs were administered without
adjuvant [14]. Thus, it appears that MCV VLPs are relatively
potent immunogens that could, in principle, be incorporated into
existing VLP-based preventive vaccine regimens.
Cell culture and small animal models for MCV replication are
not yet available and little is known about the infectious tropism of
the virus beyond the clinical inference that it can enter Merkel cells
or their precursors. To the extent that MCV reporter vector-
mediated transduction may faithfully recapitulate the MCV
infectious entry pathway, the vectors could be useful for exploring
the entry tropism of the virus in vitro and in vivo. The vectors
should also be useful for investigation of MCV virion assembly and
structure, as well as for high-yield production of infectious virions
containing MCV genomic DNA.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All samples and data for MCC
patients were collected after written consent under study protocols
approved by the institutional review boards of the University of
Pittsburgh Cancer Institute and the University Clinic of Wu¨rzberg.
For control individuals consent was not obtained, instead samples
were de-identified and analyzed anonymously.
All animal experiments were performed at Lampire (Pipersville,
PA) commercial facilities. Protocols at this facility are reviewed
and approved for use by the Lampire Institutional Animal Care
and Use Committee (IACUC) as mandated for a USDA regulated
research institution.
Virus production
MCV reporter vector stocks were produced by transfecting
human embryonic kidney cells engineered to stably express the
cDNA of SV40 T antigen (293TT) [15]. The cells were transfected
using Lipofectamine2000 (Invitrogen) according to previously-
reported methods [42]. In initial studies, plasmids pwM and ph2m
[12] expressing, respectively, codon-modified versions of the VP1
and VP2 genes of MCV strain 339, were co-transfected with a
GFP reporter plasmid, pEGFP-N1 (Clontech). Neutralization
assay stocks employed phGluc, which encodes a Gaussia luciferase
reporter gene (NEB), as a reporter plasmid. Forty-eight hours after
transfection, the cells were harvested and lysed at high density (108
cells per ml) in Dulbecco’s phosphate buffered saline (DPBS,
Invitrogen) supplemented with 9.5 mM MgCl2, 0.4% Triton X-
100 (Pierce), 0.1% RNase A/T1 cocktail (Ambion) and antibiotic-
antimycotic (Invitrogen). The cell lysate was incubated at 37uC
overnight with the goal of promoting capsid maturation [43].
Lysates containing mature capsids were clarified by centrifugation
for 10 min at 50006g. The clarified supernatant was loaded onto
a 27–33–39% iodixanol (Optiprep, Sigma) step gradient prepared
in DPBS with a total of 0.8 M NaCl. The gradients were
ultracentrifuged 3.5 hours in an SW55 rotor at 50,000 rpm
(234,0006g). Gradient fractions were screened for the presence of
encapsidated DNA using Quant-iT Picogreen dsDNA Reagent
(Invitrogen). VP1 protein concentration was determined by
comparing vector stock to bovine serum albumin standard
(BioRad) in SYPRO Ruby-stained Nupage gels (Invitrogen).
Vector stock yields were typically several mg of purified VP1 per
225 cm2 flask of transfected cells.
Vector stocks based on murine polyomavirus (MPyV) or BKV
were produced using a similar scheme. For MPyV cells were co-
transfected with plasmids pwP and ph2p [12] (carrying codon-
modified MPyV VP1 and VP2, respectively) together with
phGluc. An additional plasmid, ph3p, encoding the MPyV minor
capsid protein VP3, was also included in the co-transfection
mixture. For BKV vector stocks, plasmid pCAG-BKV (a generous
gift from Dr. Akira Nakanishi (NCGG, Japan) [28]) encoding the
capsid protein genes was co-transfected with phGluc.
In some virion production systems, capsids containing linear
fragments of cellular DNA can substantially outnumber capsids
containing the viral genome or desired reporter plasmid [43,44].
In the vector harvest procedure detailed above, unwanted capsids
associated with large segments of cellular DNA (as opposed to
reporter plasmid DNA) tend to sediment away during the 50006g
clarification step and tend to be retained toward the top of the
Optiprep gradient ([42] and unpublished results). For production
of VLPs, recovery of capsids containing cellular DNA is desirable
and was achieved by adding Benzonase (Sigma) and Plasmid Safe
(Epicentre) nucleases to the lysis buffer (0.1% each) and adjusting
the lysate to 0.8 M NaCl immediately prior to clarification. These
modifications to the harvest protocol increased VLP yield to
roughly 1 mg of VP1 per transfected 225 cm2 flask.
Maps of plasmids used in this work and detailed virus
production protocols are available from our laboratory website
,http://home.ccr.cancer.gov/LCO/..
Neutralization assay
Neutralization assays were performed using a 96-well plate
format. Sera and virus stocks were diluted in cell culture medium
(DMEM without phenol red and supplemented with 25 mM
HEPES, 10% heat-inactivated fetal bovine serum, 1% MEM non-
essential amino acids, 1% Glutamax and 1% antibiotic-antimy-
cotic, all from Invitrogen). Test sera were subjected to a series of
ten four-fold dilutions (range 1:100 to 1:2.66107). 24 ml of the
diluted serum sample were added to 96 ml of diluted reporter
vector stock. The virus/diluted serum mixture was gently agitated
then placed on ice for 1 hour. 293TT cells were seeded in 100 ml
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of culture medium at a density of 36104 cells/well in 96-well flat
bottom plates for 3–5 hours prior to addition of 100 ml of the
virus/serum mixture. Each plate also contained eight wells of cells
receiving vector stock without test serum (no serum control) and 2
wells with cells that received only culture medium (no virus
control). To minimize plate edge effects, the outer wells of the
plate were not used for the assay and were instead filled with
culture medium. Three days after virus inoculation, the plates
were thoroughly agitated and 25 ml samples of conditioned culture
supernatant were transferred to a white 96-well luminometry plate
(Perkin Elmer). A BMG Labtech Polarstar Optima luminometer
was used to inject 50 ml of Gaussia Luciferase Assay Kit substrate
(NEB), and light emission (in relative light units, RLUs) was
measured according to manufacturer instructions. Typical assay
conditions resulted in a ‘‘no serum’’ signal of roughly 500,000
RLUs with a ‘‘no virus’’ noise of ,500 RLUs.
To calculate effective concentration 50% (EC50) values, Prism
software (GraphPad) was used to fit a variable slope sigmoidal
dose-response curve to RLU values for each serum dilution series.
Curves were constrained to average no serum and no virus control
values. Each serum sample was tested in at least two independent
neutralization assay runs. A small subset of sera whose repeat EC50
values differed by more than three-fold were re-tested until their
EC50 values stabilized. For all sera, the results of the final round of
testing are shown. Although the sera used in this work were not
heat-inactivated prior to testing, analysis of a subset of human sera
showed that the assay is compatible with a 30 minute 56uC heat-
inactivation of test sera (data not shown).
BKV neutralization assays were performed using 293TT cells
with a dose of less than 50 pg of VP1 per well. The MPyV
neutralization assay was performed using 293TT cells in a similar
fashion except that sera were tested at a single dilution (1:500)
against an MPyV-Gluc vector. The MPyV-Gluc vector transduced
293TT cells and murine NIH-3T3 cells much less efficiently than
the MCV-Gluc vector and it was therefore necessary to use a dose
of 2 ng of MPyV VP1 per well. The MPyV neutralization assay
was carried out in the presence of 100 nM trichostatin A (EMD
Biosciences), a histone deacetylase inhibitor that has previously
been shown to enhance MPyV vector-mediated transduction [45].
EIAs
EIAs were performed using Immulon HB2 plates (Thermo)
coated overnight with VLPs at 100 ng/well in PBS. The wells
were blocked with PBS+0.5% nonfat dry milk (blotto). Serum
samples were diluted in blotto and incubated in EIA wells at room
temperature with orbital shaking for 45 minutes. The plates were
then washed with PBS and bound antibody was detected using
horseradish peroxidase-conjugated donkey anti-human IgG (Jack-
son) diluted 1:7500 in blotto. ABTS substrate (Roche) develop-
ment was monitored by absorbance at 405 nm with a reference
read at 490 nm.
Immunofluorescence staining
Merkel Cell carcinoma tissue sections were cut from formalin-
fixed paraffin embedded biopsies collected under a University of
Pittsburgh IRB approved protocol. Staining was performed as
described by Robertson et al. [46] with some modifications.
Briefly, slides with the formalin fixed paraffin embedded tissues
were baked for 1 hour at 60uC. Deparaffinization was performed
by rinsing twice in xylenes for 5 min, once for 30 seconds in each
of the following solutions: 100% Ethanol, 90% ethanol, 70%
Ethanol, and twice in deionized water for 30 seconds. Slides were
then placed in a jar containing 16 Target Retrieval Solution
(Dako # S6199) in a 95 degree water bath for 30 minutes. The jar
was then incubated at room temperature for 20 minutes and the
slides rinsed 3 times for 1 min in water. Sections were blocked for
10 min at 37 degrees in Protein Block solution (Dako #x0909),
incubated in primary antibody for 2 hours at 37 degrees, rinsed 3
times in PBS, and incubated in Alexa-488 or 594 conjugated
secondary antibodies at a 1:1000 dilution (Invitrogen) followed by
3 rinses in PBS. Prolong Gold Antifade with Dapi (Invitrogen) was
used as the mounting medium and slides were visualized by
Confocal microscopy using a Zeiss NLO 510 instrument. The
primary antibodies were Mouse anti-cytokeratin (Dako) used at
1:50, Purified anti-MCV T antigen monoclonal CM2B4 [10] at
1:300, and rabbit anti-MCV (VP1/VP2) generated as described in
‘‘Candidate MCV Vaccine’’ section used at 1:2000. Images of
Hela controls (T Antigen and VP1/2 transfections) and MCC
samples had identical gain and pinhole settings, however the gain
was lowered by 30% on Hela control cells transfected with T
antigen to remain in the linear range of pixel saturation.
Sera
A pool of human sera from male U.S. AB plasma donors was
purchased from Sigma (cat# H4522). IgG was purified out of the
pooled sera using a Pierce NAb Protein G Kit, according to
manufacturer’s instructions. To generate a neutralization curve,
the purified IgG (1.1 mg/ml) was standardized to the IgG content
of the original serum (8.1 mg/ml). Serum was stripped of
immunoglobulins by passage over a mixture of protein L and
protein A/G resins (Pierce).
De-identified blood donor sera were obtained from the
Columbia University and New York City Blood Banks. Individual
serum samples from paid donors visiting U.S. plasma donation
centers were purchased from Equitech-Bio and Innovative
Research. The paid donors were 69% male, 42% Caucasian,
56% African American, and had a mean age of 56 years (range
47–75). All sera were tested for antibodies against HIV, HCV,
HBV and syphilis and were found to be negative. 21 MCV
positive cases (age 14–95 years) were obtained from persons with
histologically-confirmed MCC [12]. MCV status was determined
by qPCR as previously described [2].
Candidate MCV vaccine
To generate MCV-specific serum, a rabbit was immunized with
two 300 mg doses of MCV VP1/VP2 VLPs, according to a
standard immunization schedule offered by Lampire, Inc. The first
dose was prepared in complete Freund’s adjuvant. A booster dose
was administered 3 weeks later in incomplete Freund’s adjuvant.
Immune serum was collected 10 days after the boost. Mice were
immunized twice with 80 mg of MCV VP1/VP2 VLPs. For three
mice, the first dose was prepared in complete Freund’s adjuvant.
Another two mice were primed with VLPs in PBS without
adjuvant. For all mice, the boost (4 weeks post-prime) was
administered in incomplete Freund’s adjuvant. Sera were collected
for testing 10 days after boosting. Rabbit serum specific for MPyV
VP1 was a generous gift from the lab of Dr. Thomas L. Benjamin
(Harvard) [18].
Supporting Information
Figure S1 MCV350 VP1 is defective. 293TT cells transfected
with expression plasmids encoding the VP1 proteins of MPyV,
MCV339 or MCV350 were lysed with triton X-100, then
incubated at 37uC for 20 minutes or overnight. The lysates were
subjected to Western blotting with a rabbit serum specific for
MCV VLPs. Western blotting for GFP, which is co-expressed by
the VP1 expression plasmids, is shown in the bottom panel.
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Found at: doi:10.1371/journal.ppat.1000578.s001 (0.22 MB PDF)
Figure S2 EIA versus neutralizing EC50 values for individual
sera. Serum samples were serially diluted and tested in MCV VLP
EIA or reporter vector neutralization assay. Calculated EC50
values for each serum sample are shown.
Found at: doi:10.1371/journal.ppat.1000578.s002 (0.20 MB PDF)
Figure S3 Age versus neutralizing EC50. The neutralizing EC50
values (y axis) for individual serum samples from control subjects
or MCV+MCC patients are plotted against donor age (in years, x
axis). Values for MCC patients whose tumors tested negative for
MCV DNA are also shown.
Found at: doi:10.1371/journal.ppat.1000578.s003 (0.07 MB PDF)
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